IFN- I antagonists, such as anti-IFNα (sifalimumab, rontalizumab), anti- IFNαR(anifrolumab) appear effective in autoimmune disease, and can reduce ISG expression, the expression and nuclear translocation of IRF7 can be suppressed by the IFNα/β-Ab treatment (187–190). Here, IFNAR1 is linked to autoimmune disease.